SENORESNSESenores Pharmaceuticals LimitedMediumNeutral
Announced Fri, 3 Apr · 19:41 IST

Senores Pharmaceuticals Limited has informed the Exchange regarding intimation under Regulation 30 of SEBI (LODR) Regulations, 2015

Marquee Jv AnnouncedStrategic Transactions View source PDF

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.9%1-day move
₹785.00
prior close
₹800.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.3-0.9-0.6-1.9-0.1+2.3+4.5+7.0+13.6+17.1+18.2+28.0+72.3
Up moveDown movePending
AI summary

Senores Pharmaceuticals' wholly owned US subsidiary, Senores Pharmaceuticals Inc. (SPI), has formed a new joint venture company named Amerisyn, LLC in North Carolina, USA. SPI has subscribed to 70% of the membership interest in Amerisyn, making it a step-down subsidiary of the listed company. Amerisyn was incorporated on March 5, 2026, and the subscription became effective April 2, 2026. The JV operates in the pharmaceuticals sector and does not involve any related party transactions.

Likely market impact

This represents a strategic expansion into the US pharmaceutical market through a controlled JV structure. The 70% stake gives Senores significant control over the new entity, which could contribute to future revenue growth and international market presence.